Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

apceth Names Dr Stefanos Theoharis Chief Business Officer

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Dr Stefanos Theoharis will lead apceth’s business development and business operations and promote the continued expansion of apceth’s GMP manufacturing business.

Cell-therapy company, apceth GmbH, has announced the expansion of its senior management team with the appointment of Dr Stefanos Theoharis as Chief Business Officer.

In this newly created role, Dr Theoharis will lead apceth’s business development and business operations to maximize the value of the company’s world class clinical and preclinical pipeline. He will also promote the continued expansion of apceth’s GMP manufacturing business.

Dr Theoharis brings broad experience in the life science sector from roles in leading pharma companies, biotech, investment banking and academia. He joins apceth from Antisense Pharma, where he was Head of Business Development. Before that, he held the position of Business Development Director with Roche, where he focused on deals and alliances in Emerging Technologies. He was previously an M&A Analyst in the Life Science team for Lazard.

Dr Theoharis holds a PhD in Cell and Gene Therapy from Imperial College London, where he subsequently worked as a Research Fellow, as well as acting as a transfer consultant for the London Technology Network.

“Apceth is about to start the world’s first clinical trial with genetically modified mesenchymal stem cells in cancer indications, while our trial in Critical Limb Ischemia is advancing, so it’s a very exciting time for us to welcome Stefano to the team”, said Christine Guenther, CEO of apceth. “His experience will complement our management team and help drive apceth forward.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

apceth Expands Further its GMP Manufacturing Business
GMP manufacturing license extended further to the two new highly innovative cell and gene therapy products.
Tuesday, June 23, 2015
apceth Names Ulrike Verzetnitsch as Chief Technical Officer
Ulrike Verzetnitsch will lead with immediate effect all of apceth’s production activities and manufacturing operations.
Thursday, April 30, 2015
apceth Initiates Phase II Clinical Trial for Pioneering Engineered Cell Therapy
Successfully completed Phase I clinical study and regulatory approval enable world’s first genetically-engineered cell therapy to enter Phase II.
Saturday, March 28, 2015
apceth’s First-In-Man, First-In-Class Clinical Trial with MSCs is Now Enrolling
TREAT ME Phase I/II clinical trial for patients suffering from advanced adenocarcinoma of the gastro-intestinal tract.
Monday, January 27, 2014
apceth Receives Approval for a Clinical Cancer Trial with Adult Mesenchymal Stem Cells
apceth's first innovative cellular anti-cancer drug based on modified mesenchymal stem cells enters Phase I / II of clinical testing.
Friday, June 14, 2013
apceth Starts First Phase I/II Clinical Study on Somatic Cell Therapy for pAOD
Study investigates tolerability and efficacy of apceth's somatic cell therapeutics for treatment of pAOD after angioplasty.
Tuesday, August 23, 2011
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!